Explore the Agenda

8:00 am Check In, Coffee & Light Breakfast

8:45 am Chair’s Opening Remarks

Professor, University of Zurich

8:50 am Ice Breaker

Kick off the summit by getting to know the people at your table. Each attendee will have the opportunity to briefly introduce themselves, share their role and current focus in amylin R&D, and identify the challenges they are most interested in discussing – making it easier to spot relevant peers, start conversations early and build stronger connections throughout the meeting.

From Amylin Discovery to the Current Phase II Clinical Progress to Define Amylin’s Efficacy, Tolerability & Differentiation Potential

9:00 am From Pancreatic Amyloid to Therapeutic Hormone: Lessons from the Discovery & Development of Amylin

Chief Scientific & Medical Officer, I2O Therapeutics
  • Trace the evolution of amylin from its discovery within pancreatic amyloid deposits to recognition as a co-secreted metabolic hormone, revealing how changing biological understanding transformed an apparent marker of disease into a viable therapeutic target 
  • Review the foundational pharmacology that established amylin’s roles in satiety, gastric emptying, glucagon regulation and nutrient control, highlighting the experiments and translational decisions that enabled development of the first amylinmimetic medicines
  • Reflect on the scientific and development lessons from Amylin Pharmaceuticals, including receptor uncertainty, peptide stability and formulation challenges, to identify what today’s developers should retain, or reconsider, when engineering the next generation of amylin therapeutics

9:30 am Modern Amylin Molecules: Beyond Fibrillation Toward Developable Therapeutics

Chief Scientific Officer, Perpetual Medicines
  • Review how early fibrillation challenges were addressed through sequence modification and alternative peptide backbones
  • Examine the remaining trade-offs between stability, aggregation, receptor pharmacology, concentration, formulation and manufacturability
  • Separate developability challenges of therapeutic analogues from the biological significance of endogenous amylin aggregation in diabetes and other diseases

10:00 am Speed Networking

10:45 am Morning Break & Refreshments

11:00 am Session Reserved for Eli Lilly’s Eloralintide

Executive Director, Eli Lilly

11:30 am Session Reserved for Novo’s Amylin Portfolio

Vice President, Scientific, Novo Nordisk

12:00 pm Cagrilintide Demonstrates Metabolic Benefits & Reduces Alcohol Intake in the Golden Syrian Hamster, a New Preclinical Model to Evaluate Amylin-based Therapeutics

PhD/Director - Research & Business Development, Physiogenex
  • Discussing the limitations of DIO mice and rats in the preclinical development of amylin-based therapeutics 
  • Introducing the golden Syrian hamster model to evaluate the effects of therapies on obesity, MASH/MetALD, and alcohol use disorders
  • Presenting the effects of the amylin analogue cagrilintide in this new hamster model

12:10 pm Session Reserved for Zealand Pharma’s Petrelintide

Vice President, US Medical Affairs & Medical Advisor, Zealand Pharma

Session details to be confirmed.

12:40 pm Lunch & Networking Break

Reverse-Translating Clinical Insight & Strengthening Receptor-Level Tools to Guide Next Generation Amylin Design

1:45 pm Decoding Amylin Receptor Specificity to Engineer a More Precise, Long Acting Therapeutic

Director, Platform Development, iBio
  • Explore how fully selective antibodies can distinguish between AMY1, AMY3 and calcitonin receptor activity, moving beyond broadly biased peptide agonists to identify which receptor profiles drive weight loss, tolerability and body-composition outcomes
  • Examine how parallel interrogation of G-protein and β-arrestin signaling can connect cellular mechanism with in vivo performance, enabling more rational optimization of potency, signaling bias and receptor engagement rather than relying on clinical trialand-error
  • Assess the potential of ultra-long-acting amylin antibodies to deliver infrequent dosing, sustained receptor coverage and improved treatment adherence, helping developers pursue durable efficacy while reducing adverse effects, treatment burden and weight cycling

2:15 pm Live-cell Signaling Kinetics for Elucidating Amylin Receptor Pharmacology

Research Scientist, Montana Molecular
  • Titrating RAMPs using BacMam to optimize Amylin receptor assays
  • Profiling compounds based on real-time signaling kinetics
  • Exploring mechanism of action using kinetic biosensors

3:00 pm Afternoon & Break & Scientific Poster Session

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in amylin research and advancements. To submit a poster, please contact info@hansonwade.com

3:45 pm Reverse-Translating Clinical Readouts to Refine the Next Generation of Amylin Therapeutics

Director, Scientific, Novo Nordisk
  • Compare emerging efficacy, tolerability, titration and discontinuation patterns across selective amylin agonists, balanced agonists and amylin-containing combinations, distinguishing molecule-specific effects from potential class effects 
  • Interrogate whether current clinical performance supports proposed hypotheses around receptor selectivity, exposure, signalling bias and dose escalation, identifying which mechanistic assumptions require revision 
  • Translate clinical successes and disappointments back into preclinical decisionmaking, enabling earlier programs to update target product profiles, assays and candidate-selection criteria before entering costly trials

4:15 pm Learning from the CGRP Field to Advance Amylin Receptor Pharmacology

Professor, Pharmacology, Otago University
  • Compare amylin and CGRP receptor architecture, shared RAMP biology, expression and challenges in assigning ligand selectivity
  • Apply lessons from CGRP assay development, nomenclature and receptor characterisation to improve consistency in the amylin field
  • Identify where decades of CGRP drug development can inform target validation, translational pharmacology and therapeutic differentiation

4:45 pm Chair’s Closing Remarks

Professor, University of Zurich